ArticleMolecular biology reports2025

Targeting the IL-6R/STAT3/PD-L1 axis: lobaric acid and Tocilizumab as a promising combination immunotherapy in ovarian cancer.

Ibrahim Gadashli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.